NF1 affects around 1.7 million people worldwide, with about 70% being adults ... before AZ and its partner Merck were able to ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from ... progressive genetic ...

Merck published phase 3 data on Tuesday. Investigators in China, Europe and North America randomized 94 people with TGCT to ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...

and Merck. The company, which is based in Cambridge, Mass., cut an undisclosed number of staff members in the last week, ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...